ArticleInfection and immunity2004
Enhanced mucosal delivery of antigen with cell wall mutants of lactic acid bacteria.
Article in Infection and immunity, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 63 citations in OpenAlex.
- The Immunomodulatory Effects and Applications of Probiotic Lactiplantibacillus plantarum in Vaccine Development.Probiotics and antimicrobial proteins · 2024Review
- Antitumor properties of traditional lactic acid bacteria: Short-chain fatty acid production and interleukin 12 induction.Heliyon · 2024Article
- Molecular Mechanisms of Bacterial Resistance to Antimicrobial Peptides in the Modern Era: An Updated Review.Microorganisms · 2024Review
- Probiotic performance of B. subtilis MS. 45 improves aquaculture of rainbow trout Oncorhynchus mykiss during acute hypoxia stress.Scientific reports · 2024Article
- Tetanus Toxin Fragment C: Structure, Drug Discovery Research and Production.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Recombinant lactic acid bacteria as promising vectors for mucosal vaccination.Exploration (Beijing, China) · 2021Review
- Combined use of lactic-acid-producing bacteria as probiotics and rotavirus vaccine candidates expressing virus-specific proteins.Archives of virology · 2021Review
- Article
- Genetics of Lactococci.Microbiology spectrum · 2019Review
- Comparison of Immunogenicity and Protection of Two Pneumococcal Protein Vaccines Based on PsaA and PspA.Infection and immunity · 2018Article
- A D-Alanine auxotrophic live vaccine is effective against lethal infection caused by Staphylococcus aureus.Virulence · 2018Article
- Lactic acid bacteria--20 years exploring their potential as live vectors for mucosal vaccination.Applied microbiology and biotechnology · 2015Review
- Cell wall structure and function in lactic acid bacteria.Microbial cell factories · 2014Review
- Role of commensal and probiotic bacteria in human health: a focus on inflammatory bowel disease.Microbial cell factories · 2013Review
- Actual concept of "probiotics": is it more functional to science or business?World journal of gastroenterology · 2013Review
- Development of recombinant vaccines in lactobacilli for elimination of salmonella.Bioscience and microflora · 2011Review
- A novel plasmid for delivering genes into mammalian cells with noninvasive food and commensal lactic acid bacteria.Plasmid · 2011Article
- A foreign protein incorporated on the Tip of T3 pili in Lactococcus lactis elicits systemic and mucosal immunity.Infection and immunity · 2010Article
- Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria.Nature reviews. Microbiology · 2008Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The potential of recombinant lactic acid bacteria (LAB) to deliver heterologous antigens to the immune system and to induce protective immunity has been best demonstrated by using the C subunit of tetanus toxin (TTFC) as a model antigen. Two types of LAB carriers have mainly been used, Lactobacillus plantarum and Lactococcus lactis, which differ substantially in their abilities to resist passage through the stomach and to persist in the mouse gastrointestinal tract. Here we analyzed the effect of a deficiency in alanine racemase, an enzyme that participates in cell wall synthesis, in each of these bacterial carriers. Recombinant wild-type and mutant strains of L. plantarum NCIMB8826 and L. lactis MG1363 producing TTFC intracellularly were constructed and used in mouse immunization experiments. Remarkably, we observed that the two cell wall mutant strains were far more immunogenic than their wild-type counterparts when the intragastric route was used. However, intestinal TTFC-specific immunoglobulin A was induced only after immunization with the recombinant L. plantarum mutant strain. Moreover, the alanine racemase mutant of either LAB strain allowed induction of a much stronger serum TTFC-specific immune response after immunization via the vagina, which is a quite different ecosystem than the gastrointestinal tract. The design and use of these mutants thus resulted in a major improvement in the mucosal delivery of antigens exhibiting vaccine properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.